PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28983639-3	2019	Cells treated with the Pyk2 inhibitor TAE226 and PI3K inhibitor LY294002 were used for additional experiments.	TAE226	38-44	protein tyrosine kinase 2 beta	Homo sapiens	23-27
34784956-0	2021	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.	TAE226	32-38	PTK2 protein tyrosine kinase 2	Mus musculus	0-21
34784956-9	2021	Combined TAE226 and SOR treatment reduced HCC growth both in vitro and in vivo by affecting tumour-promoting gene expression and inducing epigenetic changes via dysregulation of FAK nuclear interactome.	TAE226	9-15	PTK2 protein tyrosine kinase 2	Mus musculus	178-181
34784956-11	2021	TAE226-mediated FAK depletion and SOR-promoted MAPK down-modulation caused a decrease in the nuclear amount of HDAC1/2 and a consequent increase of the histone H3 lysine 27 acetylation, thus counteracting histone H3 lysine 27 trimethylation.	TAE226	0-6	PTK2 protein tyrosine kinase 2	Mus musculus	16-19
34784956-11	2021	TAE226-mediated FAK depletion and SOR-promoted MAPK down-modulation caused a decrease in the nuclear amount of HDAC1/2 and a consequent increase of the histone H3 lysine 27 acetylation, thus counteracting histone H3 lysine 27 trimethylation.	TAE226	0-6	histone deacetylase 1	Mus musculus	111-118
32979460-6	2020	An inhibitor of focal adhesion kinase (FAK) phosphorylation, TAE226, was used to demonstrate a relationship between extracellular adhesion perturbations and structural reactivity in the novel 3D model.	TAE226	61-67	protein tyrosine kinase 2	Homo sapiens	16-37
32979460-6	2020	An inhibitor of focal adhesion kinase (FAK) phosphorylation, TAE226, was used to demonstrate a relationship between extracellular adhesion perturbations and structural reactivity in the novel 3D model.	TAE226	61-67	protein tyrosine kinase 2	Homo sapiens	39-42
34757216-1	2021	Forty-one new focal adhesion kinase (FAK) covalent inhibitors were designed and synthesized based on FAK inhibitor TAE226.	TAE226	115-121	protein tyrosine kinase 2	Homo sapiens	14-35
34757216-1	2021	Forty-one new focal adhesion kinase (FAK) covalent inhibitors were designed and synthesized based on FAK inhibitor TAE226.	TAE226	115-121	protein tyrosine kinase 2	Homo sapiens	37-40
34757216-1	2021	Forty-one new focal adhesion kinase (FAK) covalent inhibitors were designed and synthesized based on FAK inhibitor TAE226.	TAE226	115-121	protein tyrosine kinase 2	Homo sapiens	101-104
35452915-0	2022	Design, synthesis and biological evaluation of novel FAK inhibitors with better selectivity over IR than TAE226.	TAE226	105-111	protein tyrosine kinase 2	Homo sapiens	53-56
35452915-1	2022	In this study, 28 novel focal adhesion kinase (FAK) inhibitors were designed and synthesized based on FAK inhibitor TAE226.	TAE226	116-122	protein tyrosine kinase 2	Homo sapiens	24-45
35452915-1	2022	In this study, 28 novel focal adhesion kinase (FAK) inhibitors were designed and synthesized based on FAK inhibitor TAE226.	TAE226	116-122	protein tyrosine kinase 2	Homo sapiens	47-50
35452915-1	2022	In this study, 28 novel focal adhesion kinase (FAK) inhibitors were designed and synthesized based on FAK inhibitor TAE226.	TAE226	116-122	protein tyrosine kinase 2	Homo sapiens	102-105
32784087-5	2020	Furthermore, computational docking analysis also suggested that 4o and TAE-226 displayed the similar interaction with FAK kinase domain.	TAE226	71-78	protein tyrosine kinase 2	Homo sapiens	118-121
31215459-0	2019	Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.	TAE226	64-70	PTK2 protein tyrosine kinase 2	Mus musculus	36-39
31215459-0	2019	Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.	TAE226	64-70	insulin-like growth factor I receptor	Mus musculus	40-46
31215459-1	2019	OBJECTIVE: A dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor 1 receptor (IGF-1R), TAE226, was evaluated in a panel of cancer cell lines, MIA PaCa-2 human pancreatic tumor and 4T1 murine breast tumor models.	TAE226	111-117	insulin like growth factor 1 receptor	Homo sapiens	63-100
31215459-1	2019	OBJECTIVE: A dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor 1 receptor (IGF-1R), TAE226, was evaluated in a panel of cancer cell lines, MIA PaCa-2 human pancreatic tumor and 4T1 murine breast tumor models.	TAE226	111-117	insulin like growth factor 1 receptor	Homo sapiens	102-108
31215459-7	2019	In the MIA PaCa-2 model, TAE226 inhibited phosphorylation of Y397-FAK and phosphorylation of S473-Akt as IGF-1R signaling in the cell culture in vitro and the tumor in mice.	TAE226	25-31	PTK2 protein tyrosine kinase 2	Mus musculus	66-69
31215459-7	2019	In the MIA PaCa-2 model, TAE226 inhibited phosphorylation of Y397-FAK and phosphorylation of S473-Akt as IGF-1R signaling in the cell culture in vitro and the tumor in mice.	TAE226	25-31	thymoma viral proto-oncogene 1	Mus musculus	98-101
31215459-7	2019	In the MIA PaCa-2 model, TAE226 inhibited phosphorylation of Y397-FAK and phosphorylation of S473-Akt as IGF-1R signaling in the cell culture in vitro and the tumor in mice.	TAE226	25-31	insulin-like growth factor I receptor	Mus musculus	105-111
31215459-9	2019	Similarly in the 4T1 model, TAE226 inhibited phosphorylation of Y397-FAK and S473-Akt in the cell culture in vitro and the tumor in mice.	TAE226	28-34	PTK2 protein tyrosine kinase 2	Mus musculus	69-72
31215459-9	2019	Similarly in the 4T1 model, TAE226 inhibited phosphorylation of Y397-FAK and S473-Akt in the cell culture in vitro and the tumor in mice.	TAE226	28-34	thymoma viral proto-oncogene 1	Mus musculus	82-85
30228782-9	2018	The results of TAE226, U0126 or Ly294002 treatment confirmed an essential role of FMNL3 in activation of the RhoC/FAK pathway and the subsequent promotion of CRC invasion.	TAE226	15-21	formin like 3	Homo sapiens	82-87
26096850-4	2015	beta1 integrin, focal adhesion kinase and EGFR were inhibited by AIIB2, TAE226 and Cetuximab, respectively.	TAE226	72-78	integrin subunit beta 1	Homo sapiens	0-14
29458087-7	2018	However, the tissue scores was signifcaintly decreased by FAK inhibitor TAE226.	TAE226	72-78	protein tyrosine kinase 2	Rattus norvegicus	58-61
27704688-4	2017	These abnormalities were ameliorated by dietary intervention of TAE226, a reported inhibitor of FAK.	TAE226	64-70	protein tyrosine kinase 2	Rattus norvegicus	96-99
27704688-9	2017	This was further identified by animal data that p38 activation was also abrogated by TAE226 treatment in hypercholesterolaemic rats, suggesting that FAK/p38 axis might also be involved in in vivo events.	TAE226	85-91	mitogen activated protein kinase 14	Rattus norvegicus	48-51
27704688-9	2017	This was further identified by animal data that p38 activation was also abrogated by TAE226 treatment in hypercholesterolaemic rats, suggesting that FAK/p38 axis might also be involved in in vivo events.	TAE226	85-91	protein tyrosine kinase 2	Rattus norvegicus	149-152
27704688-9	2017	This was further identified by animal data that p38 activation was also abrogated by TAE226 treatment in hypercholesterolaemic rats, suggesting that FAK/p38 axis might also be involved in in vivo events.	TAE226	85-91	mitogen activated protein kinase 14	Rattus norvegicus	153-156
26549408-4	2016	In the present article, we used Molecular Dynamic (MD) simulation method to explore the characteristic of interaction between FAK and three inhibitors (PHM16, TAE226, and ligand3).	TAE226	159-165	protein tyrosine kinase 2	Homo sapiens	126-129
29090460-3	2017	When we treated RAW 264.7 macrophages with inhibitors of various oncogenic pathways, we found that the focal adhesion kinase (FAK) inhibitors PF573228 and TAE226 could induce cell multinucleation by suppressing furrowing and cytokinesis.	TAE226	155-161	PTK2 protein tyrosine kinase 2	Mus musculus	103-124
29090460-3	2017	When we treated RAW 264.7 macrophages with inhibitors of various oncogenic pathways, we found that the focal adhesion kinase (FAK) inhibitors PF573228 and TAE226 could induce cell multinucleation by suppressing furrowing and cytokinesis.	TAE226	155-161	PTK2 protein tyrosine kinase 2	Mus musculus	126-129
27380318-5	2016	Treatment of goat fetal fibroblasts (GFbs) with a specific FAK inhibitor, TAE226, inhibited cell proliferation (p < 0.05) and induced damage to the cell morphology in a dose- and time-dependent manner.	TAE226	74-80	focal adhesion kinase 1	Capra hircus	59-62
27531475-0	2016	[Therapeutic effect of IGF-1R-targeting inhibitor (TAE226) on malignant pleural effusion in nude mice].	TAE226	51-57	insulin-like growth factor I receptor	Mus musculus	23-29
27531475-1	2016	OBJECTIVE: To study the therapeutic effect of IGF-1R inhibitor TAE226 on malignant pleural effusion (MPE) in nude mice.	TAE226	63-69	insulin-like growth factor I receptor	Mus musculus	46-52
26096850-4	2015	beta1 integrin, focal adhesion kinase and EGFR were inhibited by AIIB2, TAE226 and Cetuximab, respectively.	TAE226	72-78	epidermal growth factor receptor	Homo sapiens	42-46
24915008-6	2014	Treatment of Alport mice with TAE226, a small molecule inhibitor of FAK activation, ameliorated fibrosis and glomerulosclerosis, significantly reduced proteinuria and blood urea nitrogen levels, and partially restored GBM ultrastructure.	TAE226	30-36	PTK2 protein tyrosine kinase 2	Mus musculus	68-71
25625667-3	2015	Thus, FAK was inhibited using the pharmaco-logical inhibitor TAE226 and cytotoxicity and radiosensitization of glioblastoma cells were investigated in vitro.	TAE226	61-67	protein tyrosine kinase 2	Homo sapiens	6-9
25625667-6	2015	Efficient FAK inhibition by TAE226 mediated significant cytotoxicity and reduced sphere formation in a dose- and time-dependent manner.	TAE226	28-34	protein tyrosine kinase 2	Homo sapiens	10-13
25625667-9	2015	The results demonstrated that pharmacological FAK inhibitor TAE226 efficiently reduced clonogenicity and sphere formation in glioblastoma cells without generally modifying their radiosensitivity.	TAE226	60-66	protein tyrosine kinase 2	Homo sapiens	46-49
25625667-10	2015	However, future studies are necessary to define the potential of FAK inhibition by TAE226 or other pharmacological inhibitors in combination with radiochemotherapy.	TAE226	83-89	protein tyrosine kinase 2	Homo sapiens	65-68
26090892-0	2015	TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.	TAE226	0-6	epidermal growth factor receptor	Mus musculus	56-60
26090892-0	2015	TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.	TAE226	0-6	epidermal growth factor receptor	Mus musculus	127-131
26090892-1	2015	TAE226, a bis-anilino pyrimidine compound, has been developed as an inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-IR).	TAE226	0-6	PTK2 protein tyrosine kinase 2	Mus musculus	81-102
26090892-1	2015	TAE226, a bis-anilino pyrimidine compound, has been developed as an inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-IR).	TAE226	0-6	PTK2 protein tyrosine kinase 2	Mus musculus	104-107
26090892-1	2015	TAE226, a bis-anilino pyrimidine compound, has been developed as an inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-IR).	TAE226	0-6	insulin-like growth factor I receptor	Mus musculus	113-150
26090892-1	2015	TAE226, a bis-anilino pyrimidine compound, has been developed as an inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-IR).	TAE226	0-6	insulin-like growth factor I receptor	Mus musculus	152-158
26090892-3	2015	TAE226 was more effective against cells with mutant EGFR, including the T790M mutant, than against cells with wild-type one.	TAE226	0-6	epidermal growth factor receptor	Mus musculus	52-56
26090892-4	2015	TAE226 preferentially inhibited phospho-EGFR and its downstream signaling mediators in the cells with mutant EGFR than in those with wild-type one.	TAE226	0-6	epidermal growth factor receptor	Mus musculus	40-44
26090892-4	2015	TAE226 preferentially inhibited phospho-EGFR and its downstream signaling mediators in the cells with mutant EGFR than in those with wild-type one.	TAE226	0-6	epidermal growth factor receptor	Mus musculus	109-113
26090892-7	2015	Of interest, the L858R/T790M or delE746_A750/T790M mutant enhanced the binding affinity for TAE226 compared with the L858R or delE746_A750 mutant, resulting in the effectiveness of TAE226 against T790M mutant cells despite the T790M mutation restoring the ATP affinity for the mutant EGFR close to that for the wild-type.	TAE226	92-98	epidermal growth factor receptor	Mus musculus	284-288
26090892-7	2015	Of interest, the L858R/T790M or delE746_A750/T790M mutant enhanced the binding affinity for TAE226 compared with the L858R or delE746_A750 mutant, resulting in the effectiveness of TAE226 against T790M mutant cells despite the T790M mutation restoring the ATP affinity for the mutant EGFR close to that for the wild-type.	TAE226	181-187	epidermal growth factor receptor	Mus musculus	284-288
26090892-10	2015	In summary, we showed that TAE226 inhibited the activation of mutant EGFR and exhibited anti-proliferative activity against NSCLCs carrying EGFR mutations, including T790M mutation.	TAE226	27-33	epidermal growth factor receptor	Mus musculus	69-73
26090892-10	2015	In summary, we showed that TAE226 inhibited the activation of mutant EGFR and exhibited anti-proliferative activity against NSCLCs carrying EGFR mutations, including T790M mutation.	TAE226	27-33	epidermal growth factor receptor	Mus musculus	140-144
24915008-7	2014	Glomerular expression of MMP-9, MMP-10 and MMP-12 mRNAs was significantly reduced in TAE226 treated animals.	TAE226	85-91	matrix metallopeptidase 9	Mus musculus	25-30
24915008-7	2014	Glomerular expression of MMP-9, MMP-10 and MMP-12 mRNAs was significantly reduced in TAE226 treated animals.	TAE226	85-91	matrix metallopeptidase 10	Mus musculus	32-38
24915008-7	2014	Glomerular expression of MMP-9, MMP-10 and MMP-12 mRNAs was significantly reduced in TAE226 treated animals.	TAE226	85-91	matrix metallopeptidase 12	Mus musculus	43-49
24860788-10	2014	We then treated mice xenografted with Ph+ leukemia cells with the FAK inhibitor TAE226 in combination with a BCR-ABL TKI nilotinib.	TAE226	80-86	PTK2 protein tyrosine kinase 2	Mus musculus	66-69
24036212-9	2013	The FAK inhibitor TAE226 and the specific knockdown of Grb2 remarkably alleviated TGFbeta1-induced podocyte apoptosis.	TAE226	18-24	PTK2 protein tyrosine kinase 2	Mus musculus	4-7
24036212-9	2013	The FAK inhibitor TAE226 and the specific knockdown of Grb2 remarkably alleviated TGFbeta1-induced podocyte apoptosis.	TAE226	18-24	transforming growth factor, beta 1	Mus musculus	82-90
21454698-6	2011	Finally, our data indicate that FAK inhibitors could be used as potential therapeutic agents for patients with multiple endocrine neoplasia type 2 tumors because both, treatment with the FAK kinase inhibitor NVP-TAE226 and FAK down-regulation by siRNA reduced RET phosphorylation and signaling as well as the proliferation and survival of tumor and transfected cell lines expressing oncogenic RET.	TAE226	212-218	protein tyrosine kinase 2	Homo sapiens	187-190
23845217-4	2013	X-ray crystallographic analysis of the co-crystal structure for compound 34 revealed that the mode of interaction with the FAK kinase domain is highly similar to that observed in the complex of TAE-226.	TAE226	194-201	protein tyrosine kinase 2	Homo sapiens	123-126
22766511-0	2012	Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.	TAE226	43-49	protein tyrosine kinase 2	Homo sapiens	29-32
22766511-2	2012	In order to seek therapies targeting oral squamous cell carcinoma, we developed the novel FAK Tyr(397) inhibitor TAE226 and investigated its anti-tumor effects and mechanisms.	TAE226	113-119	protein tyrosine kinase 2	Homo sapiens	90-93
22766511-7	2012	In addition, TAE226 inhibited the expression of phospho-FAK Tyr(397) and phospho AKT Ser(473), resulting in caspase-mediated apoptosis.	TAE226	13-19	protein tyrosine kinase 2	Homo sapiens	56-59
22766511-7	2012	In addition, TAE226 inhibited the expression of phospho-FAK Tyr(397) and phospho AKT Ser(473), resulting in caspase-mediated apoptosis.	TAE226	13-19	AKT serine/threonine kinase 1	Homo sapiens	81-84
22766511-9	2012	CONCLUSIONS: Our results provide compelling evidence that FAK is critically involved in oral squamous cell carcinoma and that the FAK inhibitor TAE226 can potentially be effectively used for the treatment of oral squamous cell carcinoma.	TAE226	144-150	protein tyrosine kinase 2	Homo sapiens	58-61
22766511-9	2012	CONCLUSIONS: Our results provide compelling evidence that FAK is critically involved in oral squamous cell carcinoma and that the FAK inhibitor TAE226 can potentially be effectively used for the treatment of oral squamous cell carcinoma.	TAE226	144-150	protein tyrosine kinase 2	Homo sapiens	130-133
22705303-0	2012	Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.	TAE226	37-43	PTK2 protein tyrosine kinase 2	Mus musculus	23-26
22705303-3	2012	Since we and other groups have reported that the inhibition of FAK activity exhibited a potent anticancer effect in several cancer models, we hypothesized that TAE226, a novel ATP-competitive tyrosine kinase inhibitor designed to target FAK, can prevent the occurrence and progression of peritoneal dissemination.	TAE226	160-166	PTK2 protein tyrosine kinase 2	Mus musculus	63-66
22705303-3	2012	Since we and other groups have reported that the inhibition of FAK activity exhibited a potent anticancer effect in several cancer models, we hypothesized that TAE226, a novel ATP-competitive tyrosine kinase inhibitor designed to target FAK, can prevent the occurrence and progression of peritoneal dissemination.	TAE226	160-166	PTK2 protein tyrosine kinase 2	Mus musculus	237-240
22705303-4	2012	In vitro, TAE226 greatly inhibited the proliferation and migration of HCT116 colon cancer cells, while their adhesion on the matrix surface was minimally inhibited when FAK activity and expression was suppressed by TAE226 and siRNA.	TAE226	215-221	protein tyrosine kinase 2	Homo sapiens	169-172
22705303-8	2012	Taken together, a possible strategy for inhibiting peritoneal dissemination by targeting FAK with TAE226 appears to be applicable through anti-proliferative and anti-invasion/anti-migration mechanisms.	TAE226	98-104	PTK2 protein tyrosine kinase 2	Mus musculus	89-92
23642017-3	2013	In the present study, we investigated whether the targeted inhibition of FAK by using a specific inhibitor, TAE226, has the potential to regulate pulmonary fibrosis.	TAE226	108-114	PTK2 protein tyrosine kinase 2	Mus musculus	73-76
23642017-4	2013	TAE226 showed inhibitory activity of autophosphorylation of FAK at tyrosine 397 in lung fibroblasts.	TAE226	0-6	PTK2 protein tyrosine kinase 2	Mus musculus	60-63
23642017-5	2013	The addition of TAE226 inhibited the proliferation of lung fibroblasts in response to various growth factors, including platelet-derived growth factor and insulin-like growth factor I, in vitro.	TAE226	16-22	insulin-like growth factor 1	Mus musculus	155-183
21454698-6	2011	Finally, our data indicate that FAK inhibitors could be used as potential therapeutic agents for patients with multiple endocrine neoplasia type 2 tumors because both, treatment with the FAK kinase inhibitor NVP-TAE226 and FAK down-regulation by siRNA reduced RET phosphorylation and signaling as well as the proliferation and survival of tumor and transfected cell lines expressing oncogenic RET.	TAE226	212-218	protein tyrosine kinase 2	Homo sapiens	32-35
21454698-6	2011	Finally, our data indicate that FAK inhibitors could be used as potential therapeutic agents for patients with multiple endocrine neoplasia type 2 tumors because both, treatment with the FAK kinase inhibitor NVP-TAE226 and FAK down-regulation by siRNA reduced RET phosphorylation and signaling as well as the proliferation and survival of tumor and transfected cell lines expressing oncogenic RET.	TAE226	212-218	protein tyrosine kinase 2	Homo sapiens	187-190
21454698-6	2011	Finally, our data indicate that FAK inhibitors could be used as potential therapeutic agents for patients with multiple endocrine neoplasia type 2 tumors because both, treatment with the FAK kinase inhibitor NVP-TAE226 and FAK down-regulation by siRNA reduced RET phosphorylation and signaling as well as the proliferation and survival of tumor and transfected cell lines expressing oncogenic RET.	TAE226	212-218	ret proto-oncogene	Homo sapiens	260-263
21454698-6	2011	Finally, our data indicate that FAK inhibitors could be used as potential therapeutic agents for patients with multiple endocrine neoplasia type 2 tumors because both, treatment with the FAK kinase inhibitor NVP-TAE226 and FAK down-regulation by siRNA reduced RET phosphorylation and signaling as well as the proliferation and survival of tumor and transfected cell lines expressing oncogenic RET.	TAE226	212-218	ret proto-oncogene	Homo sapiens	393-396
19020730-0	2008	TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.	TAE226	0-6	protein tyrosine kinase 2	Homo sapiens	29-32
21338601-0	2011	Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.	TAE226	44-50	protein tyrosine kinase 2	Homo sapiens	73-76
21338601-0	2011	Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.	TAE226	44-50	insulin like growth factor 1 receptor	Homo sapiens	81-87
21338601-3	2011	In this study, we have analyzed anti-tumor effects of the novel FAK Tyr(397) inhibitor TAE226 against bone metastasis in breast cancer by using TAE226.	TAE226	87-93	protein tyrosine kinase 2	Homo sapiens	64-67
21338601-3	2011	In this study, we have analyzed anti-tumor effects of the novel FAK Tyr(397) inhibitor TAE226 against bone metastasis in breast cancer by using TAE226.	TAE226	144-150	protein tyrosine kinase 2	Homo sapiens	64-67
21338601-7	2011	Moreover, TAE226 inhibited the receptor activator for nuclear factor kappa B Ligand (RANKL) gene expression induced by parathyroid hormone-related protein (PTHrP) in bone stromal ST2 cells and blood free calcium concentration induced by PTHrP administration in vivo.	TAE226	10-16	TNF superfamily member 11	Homo sapiens	31-83
21338601-7	2011	Moreover, TAE226 inhibited the receptor activator for nuclear factor kappa B Ligand (RANKL) gene expression induced by parathyroid hormone-related protein (PTHrP) in bone stromal ST2 cells and blood free calcium concentration induced by PTHrP administration in vivo.	TAE226	10-16	TNF superfamily member 11	Homo sapiens	85-90
21338601-7	2011	Moreover, TAE226 inhibited the receptor activator for nuclear factor kappa B Ligand (RANKL) gene expression induced by parathyroid hormone-related protein (PTHrP) in bone stromal ST2 cells and blood free calcium concentration induced by PTHrP administration in vivo.	TAE226	10-16	parathyroid hormone like hormone	Homo sapiens	119-154
21338601-7	2011	Moreover, TAE226 inhibited the receptor activator for nuclear factor kappa B Ligand (RANKL) gene expression induced by parathyroid hormone-related protein (PTHrP) in bone stromal ST2 cells and blood free calcium concentration induced by PTHrP administration in vivo.	TAE226	10-16	parathyroid hormone like hormone	Homo sapiens	156-161
21338601-7	2011	Moreover, TAE226 inhibited the receptor activator for nuclear factor kappa B Ligand (RANKL) gene expression induced by parathyroid hormone-related protein (PTHrP) in bone stromal ST2 cells and blood free calcium concentration induced by PTHrP administration in vivo.	TAE226	10-16	parathyroid hormone like hormone	Homo sapiens	237-242
19729215-0	2009	3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.	TAE226	129-135	protein tyrosine kinase 2	Homo sapiens	97-118
19729215-2	2009	The aim of this study was to evaluate the radiosensitizing potential of the FAK inhibitor TAE226 in three-dimensional (3D) tumor cell cultures.	TAE226	90-96	protein tyrosine kinase 2	Homo sapiens	76-79
19729215-6	2009	Intriguingly, TAE226 only significantly radiosensitized 3D HNSCC cell cultures accompanied by a pronounced dephosphorylation of FAK, Akt and ERK1/2.	TAE226	14-20	protein tyrosine kinase 2	Homo sapiens	128-131
19729215-6	2009	Intriguingly, TAE226 only significantly radiosensitized 3D HNSCC cell cultures accompanied by a pronounced dephosphorylation of FAK, Akt and ERK1/2.	TAE226	14-20	AKT serine/threonine kinase 1	Homo sapiens	133-136
19729215-6	2009	Intriguingly, TAE226 only significantly radiosensitized 3D HNSCC cell cultures accompanied by a pronounced dephosphorylation of FAK, Akt and ERK1/2.	TAE226	14-20	mitogen-activated protein kinase 3	Homo sapiens	141-147
19729215-7	2009	CONCLUSIONS: Our data demonstrate TAE226 as potent FAK inhibitor that enhances the cellular radiosensitivity particularly of HNSCC cells grown in a 3D cell culture model.	TAE226	34-40	protein tyrosine kinase 2	Homo sapiens	51-54
19139121-6	2009	When FAK activity in those cells was inhibited by TAE226, cell growth was equally suppressed and the cells underwent apoptosis regardless of the c-KIT mutation types.	TAE226	50-56	PTK2 protein tyrosine kinase 2	Mus musculus	5-8
21338601-8	2011	These findings suggest that FAK was critically involved in osteolytic metastasis and activated in tumors, pre-osteoclasts, mature osteoclasts, and bone stromal cells and TAE226 can be effectively used for the treatment of cancer induced bone metastasis and other bone diseases.	TAE226	170-176	protein tyrosine kinase 2	Homo sapiens	28-31
21347357-11	2011	A FAK selective inhibitor TAE-226, blocked TXA(2) generation.	TAE226	26-33	PTK2 protein tyrosine kinase 2	Mus musculus	2-5
19784551-0	2010	TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.	TAE226	0-6	protein tyrosine kinase 2	Homo sapiens	30-51
19784551-4	2010	In the current study we analyzed the anti-angiogenic properties of the FAK inhibitor TAE226 on the proliferation of blood outgrowth endothelial cell (OEC) and differentiation of endothelial progenitor cells (EPC), derived from peripheral blood CD133(+) cells, tube formation and on neovascularization in a HT29 xenotransplant model.	TAE226	85-91	protein tyrosine kinase 2	Homo sapiens	71-74
19784551-12	2010	Since TAE226 has been shown to inhibit the PI3 kinase, Akt kinase, mTor pathway, addition of RAD001 may not increase this effect.	TAE226	6-12	mechanistic target of rapamycin kinase	Homo sapiens	67-71
20441998-5	2010	Infections were reduced in the presence of the FAK inhibitor, TAE226.	TAE226	62-68	protein tyrosine kinase 2	Homo sapiens	47-50
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	mechanistic target of rapamycin kinase	Homo sapiens	35-39
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	AKT serine/threonine kinase 1	Homo sapiens	41-44
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	ribosomal protein S6 kinase B1	Homo sapiens	46-52
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	mechanistic target of rapamycin kinase	Homo sapiens	94-98
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	AKT serine/threonine kinase 1	Homo sapiens	110-113
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	ribosomal protein S6 kinase B1	Homo sapiens	124-130
19020730-11	2008	Together, these data show that TAE226 has potent inhibitory effects on mTOR signaling and esophageal cancer cell growth indicating that TAE226 has potential application in esophageal cancer treatment.	TAE226	31-37	mechanistic target of rapamycin kinase	Homo sapiens	71-75
19020730-11	2008	Together, these data show that TAE226 has potent inhibitory effects on mTOR signaling and esophageal cancer cell growth indicating that TAE226 has potential application in esophageal cancer treatment.	TAE226	136-142	mechanistic target of rapamycin kinase	Homo sapiens	71-75
19020730-0	2008	TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.	TAE226	0-6	insulin like growth factor 1 receptor	Homo sapiens	37-43
19020730-0	2008	TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.	TAE226	0-6	mechanistic target of rapamycin kinase	Homo sapiens	71-75
19020730-4	2008	TAE226, a novel small molecule compound, is a potent ATP competitive inhibitor of FAK and IGF-IR.	TAE226	0-6	protein tyrosine kinase 2	Homo sapiens	82-85
19020730-4	2008	TAE226, a novel small molecule compound, is a potent ATP competitive inhibitor of FAK and IGF-IR.	TAE226	0-6	insulin like growth factor 1 receptor	Homo sapiens	90-96
19020730-5	2008	TAE226 can block FAK and IGF-IR signaling pathways.	TAE226	0-6	protein tyrosine kinase 2	Homo sapiens	17-20
19020730-5	2008	TAE226 can block FAK and IGF-IR signaling pathways.	TAE226	0-6	insulin like growth factor 1 receptor	Homo sapiens	25-31
19020730-6	2008	The purpose of this study was to explore the inhibitory effects on mTOR signaling and the mechanism of cell growth suppression by TAE226.	TAE226	130-136	mechanistic target of rapamycin kinase	Homo sapiens	67-71
19030106-0	2008	Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation.	TAE226	53-59	protein tyrosine kinase 2	Homo sapiens	26-29
18259944-2	2008	TAE226 is a novel small molecule FAK inhibitor.	TAE226	0-6	protein tyrosine kinase 2	Homo sapiens	33-36
18259944-6	2008	RESULTS: Treatment of human neuroblastoma cell lines with TAE226 resulted in a concentration dependent decrease in FAK phosphorylation, decrease in cellular viability, cell cycle arrest, and an increase in apoptosis.	TAE226	58-64	protein tyrosine kinase 2	Homo sapiens	115-118
17849451-0	2008	TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.	TAE226	0-6	epidermal growth factor receptor	Homo sapiens	74-78
17849451-4	2008	In the present study, we studied the effect of a novel FAK inhibitor, TAE226 (Novartis, Inc.), on the breast cancer cell lines.	TAE226	70-76	protein tyrosine kinase 2	Homo sapiens	55-58
17849451-7	2008	The TAE226 drug caused a dose-dependent increase of detachment and apoptosis in both BT474 and MCF-7-Vector and Src cells and in BT474-EGFR and BT474-pcDNA3 cells.	TAE226	4-10	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	112-115
17849451-7	2008	The TAE226 drug caused a dose-dependent increase of detachment and apoptosis in both BT474 and MCF-7-Vector and Src cells and in BT474-EGFR and BT474-pcDNA3 cells.	TAE226	4-10	epidermal growth factor receptor	Homo sapiens	129-139
17849451-8	2008	Additionally, TAE226 caused downregulation of Y397-FAK, FAK and activation of PARP or caspase-3 proteins.	TAE226	14-20	protein tyrosine kinase 2	Homo sapiens	51-54
17849451-8	2008	Additionally, TAE226 caused downregulation of Y397-FAK, FAK and activation of PARP or caspase-3 proteins.	TAE226	14-20	protein tyrosine kinase 2	Homo sapiens	56-59
17849451-8	2008	Additionally, TAE226 caused downregulation of Y397-FAK, FAK and activation of PARP or caspase-3 proteins.	TAE226	14-20	poly(ADP-ribose) polymerase 1	Homo sapiens	78-82
17849451-8	2008	Additionally, TAE226 caused downregulation of Y397-FAK, FAK and activation of PARP or caspase-3 proteins.	TAE226	14-20	caspase 3	Homo sapiens	86-95
17849451-11	2008	Thus, inhibition of autophosphorylation activity of FAK with the TAE226 inhibitor at 10-20 microM is effective in causing apoptosis in breast cancer cells, resistant to the Ad-FAK-CD inhibitor that can be used effectively in therapy.	TAE226	65-71	protein tyrosine kinase 2	Homo sapiens	52-55
17849451-11	2008	Thus, inhibition of autophosphorylation activity of FAK with the TAE226 inhibitor at 10-20 microM is effective in causing apoptosis in breast cancer cells, resistant to the Ad-FAK-CD inhibitor that can be used effectively in therapy.	TAE226	65-71	protein tyrosine kinase 2	Homo sapiens	176-179
18628478-4	2008	Cultured esophageal adenocarcinoma cells were treated with TAE226, a specific FAK inhibitor with an additional effect of inhibiting insulin-like growth factor-I receptor (IGF-IR), to assess its anticancer effect in vitro.	TAE226	59-65	protein tyrosine kinase 2	Homo sapiens	78-81
18628478-9	2008	The activities of FAK, IGF-IR, and AKT were suppressed by TAE226 and subsequent dephosphorylation of BAD at Ser(136) occurred, resulting in caspase-mediated apoptosis.	TAE226	58-64	protein tyrosine kinase 2	Homo sapiens	18-21
18628478-9	2008	The activities of FAK, IGF-IR, and AKT were suppressed by TAE226 and subsequent dephosphorylation of BAD at Ser(136) occurred, resulting in caspase-mediated apoptosis.	TAE226	58-64	insulin like growth factor 1 receptor	Homo sapiens	23-29
18628478-9	2008	The activities of FAK, IGF-IR, and AKT were suppressed by TAE226 and subsequent dephosphorylation of BAD at Ser(136) occurred, resulting in caspase-mediated apoptosis.	TAE226	58-64	AKT serine/threonine kinase 1	Homo sapiens	35-38
18628478-11	2008	CONCLUSIONS: These results suggest that TAE226, a dual tyrosine kinase inhibitor for FAK and IGF-IR, could become a new remedy for Barrett"s esophageal adenocarcinoma.	TAE226	40-46	protein tyrosine kinase 2	Homo sapiens	85-88
18628478-11	2008	CONCLUSIONS: These results suggest that TAE226, a dual tyrosine kinase inhibitor for FAK and IGF-IR, could become a new remedy for Barrett"s esophageal adenocarcinoma.	TAE226	40-46	insulin like growth factor 1 receptor	Homo sapiens	93-99
17849451-0	2008	TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.	TAE226	0-6	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	67-70
19030106-3	2008	Recently, a novel bis-anilino pyrimidine inhibitor, TAE226, was reported to efficiently inhibit FAK signaling, arrest tumor growth and invasion and prolong the life of mice with glioma or ovarian tumor implants.	TAE226	52-58	PTK2 protein tyrosine kinase 2	Mus musculus	96-99
19030106-4	2008	Here we describe the crystal structures of the FAK kinase bound to TAE226 and three related bis-anilino pyrimidine compounds.	TAE226	67-73	protein tyrosine kinase 2	Homo sapiens	47-50
19030106-5	2008	TAE226 induces a conformation of the N-terminal portion of the kinase activation loop that is only observed in FAK, but is distinct from the conformation in both the active and inactive states of the kinase.	TAE226	0-6	protein tyrosine kinase 2	Homo sapiens	111-114
19030106-7	2008	The presence of a glycine residue in this position contributes to the specificity of TAE226 and related compounds for FAK.	TAE226	85-91	protein tyrosine kinase 2	Homo sapiens	118-121
18006843-0	2007	Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.	TAE226	64-70	protein tyrosine kinase 2	Homo sapiens	32-53
18006843-2	2007	In the current study, we characterized the biological and therapeutic effects of a novel FAK inhibitor, TAE226.	TAE226	104-110	protein tyrosine kinase 2	Homo sapiens	89-92
18006843-5	2007	In vitro, TAE226 inhibited the phosphorylation of FAK at both Y397 and Y861 sites, inhibited cell growth in a time- and dose-dependent manner, and enhanced docetaxel-mediated growth inhibition by 10- and 20-fold in the taxane-sensitive and taxane-resistant cell lines, respectively.	TAE226	10-16	protein tyrosine kinase 2	Homo sapiens	50-53
18006843-6	2007	In vivo, FAK inhibition by TAE226 significantly reduced tumor burden in the HeyA8, SKOV3ip1, and HeyA8-MDR models (46-64%) compared with vehicle-treated controls.	TAE226	27-33	protein tyrosine kinase 2	Homo sapiens	9-12
18006843-11	2007	The novel FAK inhibitor, TAE226, offers an attractive therapeutic approach in ovarian carcinoma.	TAE226	25-31	protein tyrosine kinase 2	Homo sapiens	10-13
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	77-83	protein tyrosine kinase 2	Homo sapiens	55-58
17219439-0	2007	A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.	TAE226	65-71	protein tyrosine kinase 2	Homo sapiens	42-63
17219439-7	2007	As all glioma cell lines examined expressed phosphorylated FAK, we examined the efficacy of a novel low-molecular weight inhibitor of FAK, TAE226, against human glioma cell lines.	TAE226	139-145	protein tyrosine kinase 2	Homo sapiens	134-137
17219439-8	2007	TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines.	TAE226	0-6	protein tyrosine kinase 2	Homo sapiens	40-43
17219439-8	2007	TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines.	TAE226	0-6	AKT serine/threonine kinase 1	Homo sapiens	80-83
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	77-83	insulin like growth factor 1 receptor	Homo sapiens	63-69
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	77-83	protein tyrosine kinase 2	Homo sapiens	153-156
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	77-83	insulin like growth factor 1 receptor	Homo sapiens	161-167
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	102-108	protein tyrosine kinase 2	Homo sapiens	55-58
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	102-108	insulin like growth factor 1 receptor	Homo sapiens	63-69
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	102-108	protein tyrosine kinase 2	Homo sapiens	153-156
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	102-108	insulin like growth factor 1 receptor	Homo sapiens	161-167
17431114-5	2007	In culture, TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK (Tyr(397)).	TAE226	12-18	protein tyrosine kinase 2	Homo sapiens	81-84
17431114-6	2007	TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.	TAE226	0-6	insulin like growth factor 1	Homo sapiens	22-27
17431114-6	2007	TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.	TAE226	0-6	insulin like growth factor 1 receptor	Homo sapiens	55-61
17431114-6	2007	TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.	TAE226	0-6	AKT serine/threonine kinase 1	Homo sapiens	123-126
17431114-7	2007	TAE226 retarded tumor cell growth as assessed by a cell viability assay and attenuated G(2)-M cell cycle progression associated with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr(15)) protein expression.	TAE226	0-6	cyclin B1	Homo sapiens	147-156
17431114-7	2007	TAE226 retarded tumor cell growth as assessed by a cell viability assay and attenuated G(2)-M cell cycle progression associated with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr(15)) protein expression.	TAE226	0-6	cyclin dependent kinase 1	Homo sapiens	176-180
17431114-9	2007	Interestingly, TAE226 treatment of tumor cells containing wild-type p53 mainly exhibited G(2)-M arrest, whereas tumor cells bearing mutant p53 underwent apoptosis.	TAE226	15-21	tumor protein p53	Homo sapiens	68-71
17431114-10	2007	Induction of apoptosis by TAE226 was substantiated by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay.	TAE226	26-32	caspase 3	Homo sapiens	67-76
17431114-10	2007	Induction of apoptosis by TAE226 was substantiated by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay.	TAE226	26-32	annexin A5	Homo sapiens	141-150
17431114-12	2007	Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas.	TAE226	90-96	protein tyrosine kinase 2	Homo sapiens	70-73
17431114-12	2007	Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas.	TAE226	90-96	insulin like growth factor 1 receptor	Homo sapiens	78-84